<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347165</url>
  </required_header>
  <id_info>
    <org_study_id>AvastinDMRE</org_study_id>
    <nct_id>NCT00347165</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Age-Related Macular Degeneration</brief_title>
  <official_title>Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravitreal injection of bevacizumab is
      effective in the treatment of neovascular age related macular degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neovascular age related macular degeneration(AMD) is a important cause of legal blindness
      in adults older than 50 years. Currently the treatment is photodynamic therapy that offer
      stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been
      reported effective used as intravenous injection for AMD. But serious side effects have been
      reported with the use of this drug in oncologic patients. The intravitreal use has been
      reported in limited case reports and safety and efficacy should be determined.

      The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for
      AMD
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of visual acuity at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness at 6 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leakiness in fluorangiography at 6 months</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab intravitreal injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;50 age related macular degeneration

        Exclusion Criteria:

          -  moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non
             controlled hypertension coronary artery disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Luis Sanchez Bulnes</name>
      <address>
        <city>MExico city</city>
        <state>DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Quiroz-Mercado, MD</last_name>
      <phone>525510841400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.</citation>
    <PMID>16156152</PMID>
  </reference>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>June 30, 2006</last_update_submitted>
  <last_update_submitted_qc>June 30, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2006</last_update_posted>
  <keyword>macular degeneration</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

